← Product Code [KWY](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWY) · K023743 # SMITH & NEPHEW GLOBAL BIPOLAR SYSTEM (K023743) _Smith & Nephew, Inc. · KWY · Jan 23, 2003 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWY/K023743 ## Device Facts - **Applicant:** Smith & Nephew, Inc. - **Product Code:** [KWY](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWY.md) - **Decision Date:** Jan 23, 2003 - **Decision:** SESE - **Submission Type:** Abbreviated - **Regulation:** 21 CFR 888.3390 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Intended Use The Global Bipolar System is indicated for the following: - 1. Non-inflammatory degenerative joint disease including osteoarthritis, osteonecrosis, avascular necrosis and post traumatic arthritis; - 2. rheumatoid arthritis; - arthritis secondary to a variety of diseases and anomalies and correction 3. of functional deformity such as congenital hip dysplasia or ankylosing spondylitis; - revision procedures where other treatment or devices have failed; and 4. - treatment of proximal femoral non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement. ## Device Story Global Bipolar System is a hip joint femoral (hemi-hip) prosthesis; consists of bipolar liner, full lock ring liner, and metal retaining ring. Used with existing Smith & Nephew femoral heads. Intended for surgical implantation in patients requiring hip joint replacement or revision. Device functions as a mechanical bearing surface to restore joint mobility and function. Operates as a passive orthopedic implant; no electronic or software components. Clinical benefit includes pain relief and restoration of hip function in patients with degenerative joint disease or fractures. ## Clinical Evidence Bench testing only; no clinical data provided. Mechanical testing demonstrated equivalence to predicate devices in supporting expected in vivo loading. ## Technological Characteristics Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis. Components include bipolar liner, full lock ring liner, and metal retaining ring. Passive mechanical implant design. ## Regulatory Identification A hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis is a two-part device intended to be implanted to replace the head and neck of the femur. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a snap-fit acetabular component made of an alloy, such as cobalt-chromium-molybdenum, and ultra-high molecular weight polyethylene. This generic type of device may be fixed to the bone with bone cement (§ 888.3027) or implanted by impaction. ## Predicate Devices - Smith & Nephew Bipolar System - Centrax Bipolar System - Multipolar Bipolar System - Self-Centering Bipolar System - Ringloc Bipolar System ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K02 3743 ## Smith & Nephew, Inc. Summary of Safety and Effectiveness :Global Bipolar System #### Contact Person and Address Date of Summary: November 6, 2002 Janet Akil Director, Clinical and Regulatory Affairs Smith & Nephew, Inc., Orthopaedics Division 1450 East Brooks Road Memphis, TN 38116 (901) 399-5153 JAN 2 3 2003 # Name of Device: Global Bipolar System Common Name: Bipolar System Device Classification Name 21 CFR 888.3390 Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis ### Substantial Equivalence Information The Global Bipolar System is substantially equivalent to the following: Smith & Nephew Bipolar System, Centrax Bipolar System; Multipolar Bipolar System; Self-Centering Bipolar System; and the Ringloc Bipolar System. #### Device Description The Global Bipolar System consists of a bipolar liner, full lock ring liner, and a metal retaining ring. The system is to be used with existing femoral heads distributed by Smith & Nephew. #### Indications for Use The Global Bipolar System is indicated for the following: - Non-inflammatory degenerative joint disease including osteoarthritis, 1. osteonecrosis, avascular necrosis and post traumatic arthritis; - 2. rheumatoid arthritis; - arthritis secondary to a variety of diseases and anomalies and correction of 3. functional deformity such as congenital hip dysplasia or ankylosing spondylitis; - revision procedures where other treatment or devices have failed; and ধ: - treatment of proximal femoral non-union, femoral neck fracture, and trochanteric న. fractures of the proximal femur with head involvement. ### Technological & Performance Characteristics: The Global Bipolar System is similar to currently marketed bipolar systems. The components share the same intended use, material, and design features of one or more of the above mentioned predicates. A review of the mechanical test data indicated that the Global Bipolar System is equivalent to devices currently on the market and are capable of withstanding expected in vivo loading without failure. {1}------------------------------------------------ Image /page/1/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of a bird or abstract human figure, composed of curved lines, within a circle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the upper portion of the circle. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JAN 2 3 2003 Ms. Janet J. Akil Director, Regulatory Affairs Orthopaedic Division Smith & Nephew, Inc. 1450 Brooks Road. Memphis. Tennessee 38116 Re: K023743 Trade Name: Global Bipolar System Regulation Number: 21 CFR 888.3390 Regulation Name: Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis Regulatory Class: II Product Code: KWY Dated: November 6, 2002 Received: November 7, 2002 Dear Ms. Akil: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {2}------------------------------------------------ Page 2 – Ms. Janet J. Akil This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, sincerely yours, Mark A. Milkerss Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ 2374/3 # Global Bipolar System Indications Statement The Global Bipolar System is indicated for the following: - 1. Non-inflammatory degenerative joint disease including osteoarthritis, osteonecrosis, avascular necrosis and post traumatic arthritis; - 2. rheumatoid arthritis; - arthritis secondary to a variety of diseases and anomalies and correction 3. of functional deformity such as congenital hip dysplasia or ankylosing spondylitis; - revision procedures where other treatment or devices have failed; and 4. - న్. treatment of proximal femoral non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement. ****************************************************************************************************************************************************************************** Concurrence of CDRH, Office of Device Evaluation Prescription Use OR Over-The Counter Use (Per 21 CFR 801.109) Division Sign-Off) Division of General, Restorative and Neurological Devices (023743 10(k) Number - --- **Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWY/K023743](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWY/K023743) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com